Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramAccesswire • Thursday
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisAccesswire • 11/21/24
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma ModelsAccesswire • 11/12/24
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformAccesswire • 11/07/24
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024Accesswire • 10/22/24
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology PlatformAccesswire • 10/17/24
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment ConferenceAccesswire • 09/11/24
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateAccesswire • 08/14/24
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/13/24
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateAccesswire • 05/10/24
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/10/24
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformAccesswire • 01/17/24
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceAccesswire • 10/11/23
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAccesswire • 09/05/23
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/13/23
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight SeriesAccesswire • 07/05/23
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateAccesswire • 05/11/23
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.Accesswire • 05/04/23
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonAccesswire • 05/03/23